drugset / Trial / NCT05140694
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
RandomizedParallel-groupDouble-blindTreatment
Summary
The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone. The SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on fatty liver disease in subjects with type 2 diabetes mellitus and MAFLD.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2024-06-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |